SURVYR

UNCY

Unicycive Therapeutics, Inc.
$3.93
+$0.13 (3.42%)Oct 21 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-33%-6%+21%+48%+75%Oct 2025Oct 2026Apr 202652w high $8.7452w low $3.35
UNCYSPY
Wall St. Highest PT $42.00 (+968.7%) Wall St. Avg PT $28.40 (+622.6%)
$3$17$30$44$57POC $5Hi $42Avg $28
Underwater Drawdown %Max DD -60.7%Current -54.1%
0.0%-60.7%
Relative Strength vs SPY-37.8% vs SPYUnderperforming
+68%0%-68%
1W
+$0.23 (6.22%)
1M
−$0.84 (17.61%)
3M
−$1.64 (29.44%)
6M
−$3.78 (49.03%)
YTD
−$1.84 (31.89%)
1Y
−$1.01 (20.45%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$3.93
Average target$28.40
+$24.47 (+622.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$13.00
Median$28.40
High$42.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-09-29 · HC Wainwright & Co. reiterated Buy on UNCY
Reiterated
2026-08-20 · Benchmark reiterated Speculative Buy on UNCY
Reiterated
2026-08-13 · Guggenheim reiterated Buy on UNCY
Reiterated
2026-08-13 · B. Riley Securities reiterated Buy on UNCY
Reiterated
2026-07-01 · Benchmark reiterated Speculative Buy on UNCY
Reiterated
2026-07-01 · Noble Capital Markets reiterated Outperform on UNCY
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$107.7M
P/E (next 12 months, estimated)2.3
52-week range$3.35 – $8.74
Dividend yieldNo dividend
Average analyst price target$28.40 (+623%)

What they do

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for UNCY yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

UNCY earningsNext report in 15 days
Next report
Thu Nov 12, 2026Before the open
EPS consensus-$0.35 range -$0.66–-$0.23
Revenue consensus$0 9 analysts
Last 4 quarters · EPS vs estimate
Aug 12, 2026-$0.06est -$0.33+81.7%Above estimates
Mar 30, 2026-$0.82est -$0.46−80.0%Below estimates
Nov 12, 2025-$0.33est -$0.53+37.7%Above estimates
Aug 14, 2025-$0.52est -$0.70+25.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 13:43:49 ET
24-0824-1125-0325-0525-0825-1126-0326-08-2.601.50
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
PR Newswire · Oct 24
Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit
PR Newswire · Oct 21
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law Firm
PR Newswire · Oct 20
Rating changes
Reiterated
2026-09-29 · HC Wainwright & Co. reiterated Buy on UNCY
Reiterated
2026-08-20 · Benchmark reiterated Speculative Buy on UNCY
Reiterated
2026-08-13 · Guggenheim reiterated Buy on UNCY
Reiterated
2026-08-13 · B. Riley Securities reiterated Buy on UNCY
Reiterated
2026-07-01 · Benchmark reiterated Speculative Buy on UNCY
Reiterated
2026-07-01 · Noble Capital Markets reiterated Outperform on UNCY

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 13:43:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026